PURPOSE: To evaluate the efficacy and safety of proton-beam therapy for locoregionally advanced esophageal cancer. PATIENTS AND METHODS: The subjects were 51 patients with esophageal cancer who were treated between 1985 and 2005 using proton beams with or without X-rays. All but one had squamous cell carcinoma. Of the 51 patients, 33 received combinations of X-rays (median 46 Gy) and protons (median 36 GyE) as a boost. The median total dose of combined X-rays and proton radiation for these 33 patients was 80 GyE (range 70-90 GyE). The other 18 patients received proton-beam therapy alone (median 79 GyE, range 62-98 GyE). RESULTS: Treatment interruption due to radiation-induced esophagitis or hematologic toxicity was not required for any patient. The overall 5-year actuarial survival rate for the 51 patients was 21.1% and the median survival time was 20.5 months (95% confidence interval 10.9-30.2). Of the 51 patients, 40 (78%) showed a complete response within 4 months after completing treatment and seven (14%) showed a partial response, giving a response rate of 92% (47/51). The 5-year local control rate for all 51 patients was 38.0% and the median local control time was 25.5 months (95% confidence interval 14.6-36.3). CONCLUSION: The results suggest that proton-beam therapy is an effective treatment for patients with locally advanced esophageal cancer. Further studies are required to determine the optimal total dose, fractionation schedules, and best combination of proton therapy with chemotherapy.
PURPOSE: To evaluate the efficacy and safety of proton-beam therapy for locoregionally advanced esophageal cancer. PATIENTS AND METHODS: The subjects were 51 patients with esophageal cancer who were treated between 1985 and 2005 using proton beams with or without X-rays. All but one had squamous cell carcinoma. Of the 51 patients, 33 received combinations of X-rays (median 46 Gy) and protons (median 36 GyE) as a boost. The median total dose of combined X-rays and proton radiation for these 33 patients was 80 GyE (range 70-90 GyE). The other 18 patients received proton-beam therapy alone (median 79 GyE, range 62-98 GyE). RESULTS: Treatment interruption due to radiation-induced esophagitis or hematologic toxicity was not required for any patient. The overall 5-year actuarial survival rate for the 51 patients was 21.1% and the median survival time was 20.5 months (95% confidence interval 10.9-30.2). Of the 51 patients, 40 (78%) showed a complete response within 4 months after completing treatment and seven (14%) showed a partial response, giving a response rate of 92% (47/51). The 5-year local control rate for all 51 patients was 38.0% and the median local control time was 25.5 months (95% confidence interval 14.6-36.3). CONCLUSION: The results suggest that proton-beam therapy is an effective treatment for patients with locally advanced esophageal cancer. Further studies are required to determine the optimal total dose, fractionation schedules, and best combination of proton therapy with chemotherapy.
Authors: S Vatnitsky; J Siebers; D Miller; M Moyers; M Schaefer; D Jones; S Vynckier; Y Hayakawa; S Delacroix; U Isacsson; J Medin; A Kacperek; A Lomax; A Coray; H Kluge; J Heese; L Verhey; I Daftari; K Gall; G Lam; T Beck; G Hartmann Journal: Radiother Oncol Date: 1996-11 Impact factor: 6.280
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: H Tsujii; H Tsuji; T Inada; A Maruhashi; Y Hayakawa; Y Takada; J Tada; S Fukumoto; H Tatuzaki; K Ohara Journal: Int J Radiat Oncol Biol Phys Date: 1993-01 Impact factor: 7.038
Authors: James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani Journal: Curr Oncol Rep Date: 2011-06 Impact factor: 5.075
Authors: Frank Heinzelmann; Daniela Thorwarth; Ulf Lamprecht; Theodor W Kaulich; Jörg Fuchs; Guido Seitz; Martin Ebinger; Rupert Handgretinger; Michael Bamberg; Martin Weinmann Journal: Strahlenther Onkol Date: 2011-10-29 Impact factor: 3.621
Authors: M Mizumoto; T Okumura; E Ishikawa; T Yamamoto; S Takano; A Matsumura; Y Oshiro; H Ishikawa; H Sakurai; K Tsuboi Journal: Strahlenther Onkol Date: 2013-07-05 Impact factor: 3.621
Authors: M Mizumoto; H Hashii; M Senarita; S Sakai; T Wada; T Okumura; K Tsuboi; H Sakurai Journal: Strahlenther Onkol Date: 2013-02-28 Impact factor: 3.621
Authors: Y Demizu; O Fujii; K Terashima; M Mima; N Hashimoto; Y Niwa; T Akagi; T Daimon; M Murakami; N Fuwa Journal: Strahlenther Onkol Date: 2013-12-22 Impact factor: 3.621